Teladoc acquires Best Doctors in $440M deal to boost international clout

Teladoc | June 19, 2017

In its largest acquisition to date and one of the top digital health deals of the year, Teladoc has acquired second opinion service Best Doctors in a $440 million deal, including $375 million cash and $65 million in equity. As 40 percent of Best Doctors’ revenue is generated outside the U.S., the deal is intended to boost Teladoc’s international clout and provide telehealth cross selling opportunities for both companies.

Spotlight

A stand-out digital solution is one that is highly valued by the patient, seamlessly integrated, and delivers measurable results, such as improved health outcomes. Pharmaceutical clients come to Atlantis Healthcare because they want to deliver patient support solutions that stand out within the digital health space, while also complying with in-market regulatory requirements and the challenges of value based care. Atlantis has an established process and infrastructure to design, implement and measure digital tools. We believe that increasing the personal relevance of these tools can lead to improved health outcomes through the promotion of behavior change.


Other News
HEALTH TECHNOLOGY

MCI Onehealth Partners with MDClone to Accelerate Research through Global Clinical Intelligence Offering

MCI Onehealth Technologies, Inc. | July 29, 2022

MCI Onehealth Technologies Inc. a clinician-led healthcare technology company focused on increasing access to and quality of healthcare, and MDClone, a digital health company and leader in synthetic data, are pleased to announce an advanced clinical intelligence offering for their global partners. This offering combines real-world health insights with mirrored synthetic data to power deeper research and inspire novel therapeutic development. “MCI’s collaboration with MDClone will provide our partners with greater access to high-value data-insights-as-a-service for an array of research, clinical and data science needs. Whether through MCI’s clinic network, international healthcare providers, or pharmaceutical, life sciences and biotech partners, our mutually enhanced insights will help to quickly translate healthcare data and research into improved health and quality of life for patients.” Dr. Alexander Dobranowski, MD, Chief Executive Officer of MCI The real-world patient health journeys that MCI’s tech-enabled network is able to capture offer a comprehensive picture to researchers, who can benefit from a fuller perspective. The partnership between MCI and MDClone will leverage MDClone’s technology to load, organize and protect MCI-generated patient data and use this data to help find insights to improve care. In addition, MCI and MDClone intend to work together to improve data collection and curation to better serve the needs of applied healthcare research. MDClone offers clients robust, detailed data for thorough end-to-end, real-world analysis. Using the MDClone ADAMS Platform analytics tools and synthetic data capabilities, clinicians, researchers, and healthcare professionals can explore healthcare data more efficiently to accelerate real-world evidence processes. With synthetic data capabilities at the forefront, users can leverage self-service tools to access, analyze, and share information without privacy concerns. Additionally, the real-time identification and extraction of information about a specific population of interest allows users at healthcare systems to overcome some of the common barriers that can slow clinical data projects’ progress. “We’re thrilled to partner with innovators like MCI in the healthcare and life science industries and beyond. Together, we can provide tailored clinical insights that meet clients’ needs, and from those insights, MDClone can generate synthetic data that researchers can use to better understand disease progression, enhance care delivery, and develop new products that can improve patient outcomes,” said Josh Rubel, Chief Operating Officer of MDClone. In keeping with its objective to be a preeminent health technology leader, MCI nurtures international opportunities to leverage its vast pool of high-quality structured clinical information. The MDClone ADAMS Platform’s unique ability to convert datasets and cohorts of interest into synthetic files that are statistically comparable to the original data, but composed entirely of artificial patients, aids in broader and more secure access and opens the doors to third-party access and larger-scale research impact. MCI’s audience for health insights continues to grow in Canada and will further benefit from access to MDClone’s global roster of top-tier health system and pharma relationships. The collaboration with MDClone will accelerate MCI’s entry into the clinical insights and analytics sectors in the United States of America and Israel, including potential access to headquarter-level decision-makers of global pharma and life science leaders. “Through this commercial arrangement, we each have the benefit of immediate introduction to the active client rosters of the other, and we each gain a superior — and unique — offering to acquire new partners, fueling the expansion of MCI’s health insight services into international markets,” added Dr. Dobranowski. About MCI MCI is a healthcare technology company focused on empowering patients and doctors with advanced technologies to increase access, improve quality, and reduce healthcare costs. As part of the healthcare community for over 30 years, MCI operates one of Canada’s leading primary care networks with nearly 260 physicians and specialists, serves more than one million patients annually and had nearly 300,000 telehealth visits last year, including online visits via mciconnect.ca. MCI additionally offers an expanding suite of occupational health service offerings that support a growing list of nearly 600 corporate customers. Led by a proven management team of doctors and experienced executives, MCI remains focused on executing a strategy centered around acquiring technology and health services that complement the company’s current roadmap. About MDClone MDClone offers an innovative, self-service data analytics environment powering exploration, discovery, and collaboration throughout healthcare ecosystems cross-institutionally and globally. The powerful underlying infrastructure of the MDClone ADAMS Platform allows users to overcome common barriers in healthcare in order to organize, access, and protect the privacy of patient data while accelerating research, improving operations and quality, and driving innovation to deliver better patient outcomes. Founded in Israel in 2016, MDClone serves major health systems, payers, and life science customers in the United States, Canada, and Israel.

Read More

FUTURE OF HEALTHCARE

The Department of Health - Abu Dhabi collaborates with a leading healthcare company to boost health technology and clinical research

The Department of Health - Abu Dhabi | June 17, 2022

The Department of Health – Abu Dhabi (DoH), the regulator of healthcare in the emirate, signed a Declaration of Collaboration with Johnson & Johnson Middle East FZ-LLC, to support Abu Dhabi's vision in developing a regional hub for clinical research and data generation. The new strategic collaboration seeks to bring innovative treatments and breakthrough solutions to the UAE and the MENA region as well as exchange knowledge across the healthcare sector. Witnessed by HE Abdulla bin Mohammed Al Hamed, Chairman of the Department of Health – Abu Dhabi (DoH), the signing ceremony happened during the BIO International Convention 2022 which took place between June 13-16 in San Diego, California, U.S. The Declaration of Collaboration between the parties was signed by Dr. Asma Al Mannaei, Executive Director, Research and Innovation Centre at DoH and Jamie Phares, Managing Director of Janssen GCC, one of the pharmaceutical companies of Johnson and Johnson. Headed by HE Abdulla bin Mohammed Al Hamed, Chairman of the Department of Health – Abu Dhabi (DoH), the Abu Dhabi delegation comprised of government officials is visiting the USA this month to explore prospects of joint collaboration within the framework of healthcare at large and life science in specific. Through these strategic collaborations, DoH and Johnson & Johnson Middle East FZ-LLC will explore key potential areas of interest to develop short and long-term projects in the generation of Data and Real-World Evidence (RWE). Through international collaborations, Abu Dhabi seeks to lead research groups supported by global partners to establish the strength and sustainability of the healthcare sector as well as provide quality care to patients. "We are pleased with all that we have achieved during the Abu Dhabi Life Science Mission thus far. Our collaborations with leading healthcare companies echo Abu Dhabi's ongoing efforts to position itself as a leading life science destination as well as an incubator for innovation. Through our collaboration with Johnson and Johnson Middle East FZ-LLC, we aim to further improve the resilience and sustainability of the healthcare sector as well as provide quality care to patients in Abu Dhabi and worldwide." Dr. Asma Al Mannaei, Executive Director, Research and Innovation Centre at the Department of Health – Abu Dhabi (DoH)

Read More

HEALTH TECHNOLOGY

HeartBeam Expands Patient Population for Emergency Department Software Technology Solution

HeartBeam, Inc. | July 04, 2022

HeartBeam, Inc. a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, announced that HeartBeam is expanding the available patient population for the Company’s Emergency Department software technology solution. In evaluating the ECG database for the clinical validation of HeartBeam’s platform technology, a significant portion of consecutive patients fell into the category of unstable angina, a serious cardiac condition. In light of the most recent 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain and in consultation with its clinical advisors, HeartBeam elected to include the full data set for clinical validation studying in support of the 510K submission. The expanded scope of the clinical validation study will provide access to a broader patient population for HeartBeam’s technology once cleared by the FDA. Due to the expanded available patient population, HeartBeam expects to file a 510K with the full data set for clinical validation no later than August 15, 2022 and does not affect the timeline for 510K submission of the Telehealth product. “It is important to include unstable angina as a diagnosis for analysis. Patients with unstable angina may have subtle electrical changes brought on by ischemia without definitive injury to the cardiac tissue. Given HeartBeam’s advanced technology solution, there is potential to identify patients who cannot be diagnosed by traditional ECG capabilities but may require intervention.” Russell Jones, MD, Interventional Cardiologist, Chair of the Ischemia Performance Improvement Committee at Phoebe Putney Health System HeartBeam’s platform technology is anticipated to assist physicians in identifying patients who present with chest pain to facilitate rapid detection of a heart attack and determine an appropriate treatment regimen. Chest pain is the second most common reason for an emergency department visit, with high costs associated with these visits. HeartBeam’s software solution may offer more accurate heart attack detection to triage patients and expedite treatment. The HeartBeam technology platform has not yet been evaluated by the FDA and is not approved for clinical use in the USA or other global geographies. “We believe our commercialization path is on track,” said Branislav Vajdic, PhD, CEO and founder. “The decision to include the broader patient population does not impact the scheduled submission for HeartBeam’s core technology platform for our Telehealth solution, which remains on schedule to submit in Q4 2022.” About HeartBeam, Inc. HeartBeam, Inc. is a development stage digital healthcare company with proprietary ECG telemedicine technology that will redefine the way high risk cardiovascular patients are diagnosed in an ambulatory setting at any time and any place. Its breakthrough solution employs a reusable, credit card sized, 3D vector ECG recording device and cloud-based software capable of assisting a physician in diagnosing a wide range of cardiovascular disease. HeartBeam is initially focusing on a huge unmet need of helping diagnose heart attacks in patients outside of a medical institution. No single lead ECG technology can offer this value to patients and their physicians. This underserved market is several times larger than the cardiac arrhythmia detection market based on the prevalence of patients with coronary artery disease at high risk of heart attack.

Read More

HEALTH TECHNOLOGY

Essentia Health Selects Press Ganey as Patient Experience and Nursing Excellence Partner

pressganey | July 07, 2022

Press Ganey, renowned leader in patient, member, employee and consumer experience across the healthcare ecosystem announced it has entered into a multi-year agreement to provide technology, counsel and additional knowledge resources to Essentia Health, an integrated healthcare system serving patients in Minnesota, Wisconsin and North Dakota. Effective July 1, Press Ganey will support Essentia Health through rapid patient experience transformation and nursing excellence across the health system’s 14 hospitals, 72 clinics and 12 care facilities. “The best collaborations create something bigger than the sum of what each partner can create on their own, and I’m incredibly excited to see the great, industry-leading work that the Essentia Health and Press Ganey teams are going to do together,” said Lanie Dixon, Vice President of Patient Experience, Essentia Health. “Press Ganey’s unparalleled expertise in healthcare industry benchmarking, leading-edge technology and wealth of knowledge and resources will help us drive meaningful organizational change for our patients, physicians, and nurses, as Essentia continues its journey to Magnet Recognition® status.” Press Ganey partners with 98% of hospitals recognized by the American Nurses’ Association’s Magnet program, which recognizes excellence in nursing. Press Ganey will support Essentia Health through an integrated, multifaceted approach, including Dynamic Surveying: Customizable, digital surveys tailored to patients’ unique experiences. Narrative Dx: Artificial Intelligence (AI)-driven Natural Language Processing (NLP) to quickly and efficiently derive insights from patient feedback. National Database of Nursing Quality Indicators® (NDNQI®): Press Ganey’s proprietary national database of 250+ nursing measures and quality indicators to get unit-level analysis to help improve patient outcomes. Transparency: A technology platform that publishes authentic ratings and reviews from real patient experience surveys to provider profiles and directories, helping earn patient trust and driving appointment scheduling. Reputation Management: A cutting-edge, purpose-built for healthcare tool that captures patient sentiment and comments from reviews and social media sites into one consolidated dashboard to enable fast responses to online feedback. “We’re thrilled to partner with and support an industry leader in Essentia Health as they track their end-to-end patient journey and improve nursing excellence system-wide. Our integrated technology platform will provide the award-winning Essentia team with the ability to monitor the connections between patient and consumer experience and high-quality care, so they can continue to serve their communities in profound ways.” Dan Litwer, chief client officer, Press Ganey About Press Ganey Press Ganey invented the healthcare performance improvement movement over 35 years ago. Today it offers an integrated suite of solutions that address safety, clinical excellence, patient experience and workforce engagement. The company works with more than 41,000 healthcare facilities in its mission to reduce patient suffering and enhance caregiver resilience to improve the overall safety, quality and experience of care. About Essentia Health Essentia Health is an integrated health system serving patients in Minnesota, Wisconsin, and North Dakota. Headquartered in Duluth, Minnesota, Essentia Health combines the strengths and talents of 14,100 employees, including more than 2,100 physicians and advanced practitioners, who serve our patients and communities through the mission of being called to make a healthy difference in people’s lives. The organization lives out its mission by having a patient-centered focus at 14 hospitals, 72 clinics, six long-term care facilities, three assisted living facilities, three independent living facilities, six ambulance services, 20 retail pharmacies, and one research institute.

Read More

Spotlight

A stand-out digital solution is one that is highly valued by the patient, seamlessly integrated, and delivers measurable results, such as improved health outcomes. Pharmaceutical clients come to Atlantis Healthcare because they want to deliver patient support solutions that stand out within the digital health space, while also complying with in-market regulatory requirements and the challenges of value based care. Atlantis has an established process and infrastructure to design, implement and measure digital tools. We believe that increasing the personal relevance of these tools can lead to improved health outcomes through the promotion of behavior change.

Resources